SCI REP:人类ATP6V1A基因在胃癌中的表达和转录调控

2017-06-07 MedSci MedSci原创

最近的研究表明,胃癌(GC)的侵袭和转移与一种多亚基液泡H + -ATPase(V-ATPase)密切相关。由于人类ATP6V1A基因在GC中编码V-ATP的酶催化亚基A,因此,我们研究了人类ATP6V1A基因的表达和作用。

最近的研究表明,胃癌(GC)的侵袭和转移与一种多亚基液泡H + -ATPase(V-ATPase)密切相关。由于人类ATP6V1A基因在GC中编码V-ATP的酶催化亚基A,因此,我们研究了人类ATP6V1A基因的表达和作用。我们发现,与正常人相比,GCs中ATP6V1A的表达水平显着升高,但ATP6V1A表达水平较高的GC患者预后较好。基因组分析显示APT6V1A拷贝数在一小部分GC患者中增加,并且在极少数量的换这种拷贝数丢失。此外,ATP6V1A拷贝数与其mRNA水平呈正相关。为了探究ATP6V1A在GC中过表达的其他机制,我们研究了转录因子YY1和ATP6V1A之间的关系,发现YY1的mRNA的表达与ATP6V1A的mRNA的表达之间有显着相关性。为了验证YY1转录调控ATP6V1A,我们发现ATP6V1A核心启动子区域含有三个YY1结合位点。此外,RNAi介导的GC细胞中YY1的敲低显着降低ATP6V1A mRNA和蛋白表达,而YY1过表达则增加ATP6V1A的表达水平。总之,YY1可能在ATP6V1A表达中发挥重要的调节作用,在GC中具有潜在的机制和临床意义。

原文出处:

Pin Wang,Jian-Hua Mao,Xiaoping Zou,1et al.Expression and Transcriptional Regulation of Human ATP6V1A Gene in Gastric Cancers.[J]Scientific Reports.2017 June 7.DOI:10.1038/s41598-017-03021-3

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1926793, encodeId=00d61926e938d, content=<a href='/topic/show?id=c41a933e689' target=_blank style='color:#2F92EE;'>#转录调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93376, encryptionId=c41a933e689, topicName=转录调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Dec 12 06:35:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747247, encodeId=cb2e1e4724758, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Tue Jan 23 02:35:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461661, encodeId=d6f114616616b, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Fri Jun 09 09:35:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208131, encodeId=91b320813104, content=文章很好,拜读了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jun 08 09:58:06 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1926793, encodeId=00d61926e938d, content=<a href='/topic/show?id=c41a933e689' target=_blank style='color:#2F92EE;'>#转录调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93376, encryptionId=c41a933e689, topicName=转录调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Dec 12 06:35:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747247, encodeId=cb2e1e4724758, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Tue Jan 23 02:35:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461661, encodeId=d6f114616616b, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Fri Jun 09 09:35:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208131, encodeId=91b320813104, content=文章很好,拜读了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jun 08 09:58:06 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
    2018-01-23 mjldent
  3. [GetPortalCommentsPageByObjectIdResponse(id=1926793, encodeId=00d61926e938d, content=<a href='/topic/show?id=c41a933e689' target=_blank style='color:#2F92EE;'>#转录调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93376, encryptionId=c41a933e689, topicName=转录调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Dec 12 06:35:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747247, encodeId=cb2e1e4724758, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Tue Jan 23 02:35:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461661, encodeId=d6f114616616b, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Fri Jun 09 09:35:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208131, encodeId=91b320813104, content=文章很好,拜读了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jun 08 09:58:06 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
    2017-06-09 listen320
  4. [GetPortalCommentsPageByObjectIdResponse(id=1926793, encodeId=00d61926e938d, content=<a href='/topic/show?id=c41a933e689' target=_blank style='color:#2F92EE;'>#转录调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93376, encryptionId=c41a933e689, topicName=转录调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Dec 12 06:35:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747247, encodeId=cb2e1e4724758, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Tue Jan 23 02:35:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461661, encodeId=d6f114616616b, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Fri Jun 09 09:35:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208131, encodeId=91b320813104, content=文章很好,拜读了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jun 08 09:58:06 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
    2017-06-08 1e10c84am36(暂无匿称)

    文章很好,拜读了

    0

相关资讯

Oncogene:TLR2与胃癌肿瘤细胞生长有关

Toll样受体(TLRs)是调节先天免疫反应的关键调节因素,在包括胃癌在内的许多炎症相关恶性疾病中均发现其失调。但是促进人胃癌发病的特异性TLRs以及其分子靶标尚未发现。

Ann Oncol:胃癌新辅助化疗:更优获益方案和更优疗程?

局限期胃癌完全切除对治愈而言非常关键,目前局部进展期胃癌标准治疗包括D2切除+辅助化疗、围手术期化疗+手术和手术+术后放化疗。不过浆膜阳性肿瘤即便D2切除+S1辅助化疗,预后仍较差。理论上术前化疗后行手术治疗较术后化疗更获益,日本的Aoyama教授在annals of oncology上发表研究,试图明确胃癌新辅助化疗获益的最优方案和最优疗程。几项日本II期研究表明顺铂+S1(CS)在转移性胃癌新

Brit J Surg:类胰蛋白酶可用来评估胃癌预后

肥大细胞在各种恶性肿瘤的发展中起重要作用,但是对评估胃癌的预后价值尚不清楚。近期发表在外科权威期刊《British Journal of Surgery》的一项研究将类胰蛋白酶的表达作为肥大细胞活性的指标进行评估,来了解类胰蛋白酶是否可以作为评估胃癌预后的一个有效指标。

ASCO2017:饮酒由醛脱氢酶2基因型调控:胃癌的潜在危险因素?

在初步分析中观察到了饮酒与胃癌风险之间的剂量反应关系。然而,ALDH2基因型不能改变饮酒情况。

Eur J Cancer:高温腹腔内化疗治疗胃癌的疗效及很大获益人群

高温腹腔内化疗(HIPEC)已用于预防和治疗胃癌腹腔转移,美国Desiderio教授在Eur J Cancer杂志发表meta分析,证实HIPEC可带来生存获益以及最大获益人群,明确腹腔转移者完全细胞减灭术是生存的关键因素,强调未来研究应明确HIPEC治疗时患者的选择标准。

Gastroenterology:早发型弥漫性胃癌基因突变特征

早发型弥漫性胃癌患者CDH1和 TGFBR1基因突变风险较高,CDH1突变对患者生存期影响较大是导致临床病情恶化的主要因素